Chinese pharmaceutical company: Subsidiary Tianfang Pharmaceuticals obtains registration certificate for Dabigatran Etexilate Capsules.

Chinese pharmaceutical company announcement, recently, its wholly-owned subsidiary, Tianfang Pharma, received two "Drug Registration Certificates" for Dapagliflozin tablets issued by the National Medical Products Administration. The National Medical Products Administration accepted the registration application for this drug in May 2024. As of the date of this announcement, the total investment in raw materials and formulation projects for this drug is approximately 28 million yuan.